NCT02683395View on ClinicalTrials.gov

A Study of PLX51107 in Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Solid TumorsAcute Myeloid LeukemiaMyelodysplastic SyndromeNon-Hodgkin's Lymphoma
Interventions
DRUG

PLX51107

Trial Locations (5)

10032

Columbia University Medical Center, New York

19107

Thomas Jefferson University, Philadelphia

29425

MUSC/ Hollings Cancer Center, Charleston

43212

The Ohio State University Stephanie Spielman Comprehensive Breast Center, Columbus

78229

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors

Lead Sponsor

Plexxikon
All Listed Sponsors
lead

Plexxikon

INDUSTRY

NCT02683395 - A Study of PLX51107 in Advanced Malignancies | Biotech Hunter | Biotech Hunter